- Home
- CCCC vs FNGR Comparison
CCCC vs FNGR Comparison
Compare CCCC & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- FNGR
- Stock Information
- Founded
- CCCC 2015
- FNGR 2016
- Country
- CCCC United States
- FNGR Singapore
- Employees
- CCCC N/A
- FNGR N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- FNGR Computer Software: Prepackaged Software
- Sector
- CCCC Health Care
- FNGR Technology
- Exchange
- CCCC Nasdaq
- FNGR Nasdaq
- Market Cap
- CCCC 104.4M
- FNGR 87.9M
- IPO Year
- CCCC 2020
- FNGR N/A
- Fundamental
- Price
- CCCC $2.46
- FNGR $1.42
- Analyst Decision
- CCCC Buy
- FNGR
- Analyst Count
- CCCC 2
- FNGR 0
- Target Price
- CCCC $8.00
- FNGR N/A
- AVG Volume (30 Days)
- CCCC 1.5M
- FNGR 486.0K
- Earning Date
- CCCC 08-07-2025
- FNGR 07-15-2025
- Dividend Yield
- CCCC N/A
- FNGR N/A
- EPS Growth
- CCCC N/A
- FNGR N/A
- EPS
- CCCC N/A
- FNGR N/A
- Revenue
- CCCC $34,240,000.00
- FNGR $35,692,374.00
- Revenue This Year
- CCCC N/A
- FNGR N/A
- Revenue Next Year
- CCCC N/A
- FNGR N/A
- P/E Ratio
- CCCC N/A
- FNGR N/A
- Revenue Growth
- CCCC 16.55
- FNGR 11.55
- 52 Week Low
- CCCC $1.09
- FNGR $1.03
- 52 Week High
- CCCC $7.22
- FNGR $5.20
- Technical
- Relative Strength Index (RSI)
- CCCC 59.48
- FNGR 37.22
- Support Level
- CCCC $1.95
- FNGR $1.43
- Resistance Level
- CCCC $2.94
- FNGR $1.50
- Average True Range (ATR)
- CCCC 0.26
- FNGR 0.10
- MACD
- CCCC 0.00
- FNGR 0.01
- Stochastic Oscillator
- CCCC 51.52
- FNGR 8.92
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.